Want to take quizzes and track your credits?
The SARS-CoV-2 (COVID-19) pandemic has caused workplaces and campuses to close or shift many people to remote work. To safely reopen, surveillance testing is needed to help to identify asymptomatic and presymptomatic cases.1,2 We conducted a clinical trial to rapidly implement and scale a saliva-based method for COVID-19 surveillance testing.3 However, participation in clinical trials is often suboptimal. In prior work,4,5 opt-out framed recruitment strategies have shown promise for increasing program enrollment; this approach may leverage status quo bias. In this randomized clinical trial, we tested the effect of an opt-out framed recruitment strategy compared with a conventional opt-in strategy on enrollment and initial adherence to a COVID-19 testing program.
Sign in to take quiz and track your certificates
Accepted for Publication: April 7, 2021.
Published: June 3, 2021. doi:10.1001/jamanetworkopen.2021.12434
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Oakes AH et al. JAMA Network Open.
Corresponding Author: Allison H. Oakes, PhD, VA Health Services Research & Development Center for Health Equity Research and Promotion, Crescenz Veterans Affairs Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104 (email@example.com).
Author Contributions: Drs Oakes and Patel had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Oakes, Epstein, Evans, Patel.
Acquisition, analysis, or interpretation of data: Oakes, Ganguly, Park.
Drafting of the manuscript: Oakes, Park, Evans.
Critical revision of the manuscript for important intellectual content: Oakes, Epstein, Ganguly, Park, Patel.
Statistical analysis: Oakes, Park.
Obtained funding: Epstein, Patel.
Administrative, technical, or material support: Epstein, Ganguly, Evans.
Supervision: Epstein, Evans, Patel.
Conflict of Interest Disclosures: Dr Oakes reported receiving support from the Department of Veterans Affairs Advanced Fellowship Program in Health Services Research & Development. Dr Patel reported being a founder of Catalyst Health, a technology and behavior change consulting firm; being an advisory board member for Healthmine Services Inc, LifeVest Health, and Holistic Industries; and receiving research funding from Deloitte, which is not related to the work described in this article. No other disclosures were reported.
Funding/Support: Funding for this work was provided by the Perelman School of Medicine at the University of Pennsylvania and the University of Pennsylvania Health System through the Penn Medicine Nudge Unit.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The contents of this manuscript do not represent the views of the US Department of Veterans Affairs or the US government.
Data Sharing Statement: See Supplement 3.
Additional Contributions: Sarah Fendrich, BA, Ai Leen Oon, BA, Kayla Clark, BA, Penn Medicine, and Andrew Parambath, BA (all at Penn Medicine), assisted with COVID SAFE program administration and management. Frederic Bushman, PhD (Penn Medicine), Scott Sherrill-Mix, PhD (Penn Medicine), and the University of Pennsylvania Rapid Assay Task Force provided guidance on assay development. Dorothy Leung, MA (Penn Medicine), assisted with program administration. None of these individuals was compensated beyond their regular salary.
You currently have no searches saved.